Skyhawk Therapeutics, with laboratories in Boston (U.S.) and Basel (Tech Park Basel), is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression. Our founders are leading experts in developing small molecule therapeutics for RNA-based disease. Our first drug candidates are targeted towards cancers and neurological conditions, some of which were previously considered undruggable.
| Building | B2 |
|---|---|
| Industry | Biotech |
| Employees | 24 |
| Founding year | 2018 |
Home 
Offer 
About us 
News 
Sustainability 